Wet AMD

Biosimilar

Diabetic Eye Awareness

Diabetic Macular Edema

Diabetic Retinopathy

Geographic Atrophy

Imaging

Inherited Retinal Diseases

Europe

Ophthalmology

Retina Technology

Retinal Surgery

Uveitis

News

All News

Blogs

Media

All Videos

Case-Based Roundtable Series

Expert Interviews

Eyeviews

Insights

Medical World News

Podcasts

Rapid Readouts

Viewpoints

Conference

Conference Coverage

Conference Listing

Publications

Modern Retina Digital Edition

Supplements And Featured Publications

Resources

Between the Lines

CME/CE

EYLEA 8mg for nAMD and DME Treatment

Partners

Subscribe

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

About

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Modern Retina – Ophthalmology News, Events & Expert Insights

Facebook

LinkedIn

Spotlight

Clinical

Case Based Roundtable Series

1rem

Dilsher S. Dhoot, MD, discusses how second-generation anti-VEGF therapies like aflibercept 8 mg and faricimab demonstrate superior efficacy and durability in treating neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) cases, allowing treatment intervals to extend by 2 to 3 weeks, improving anatomical outcomes, and reducing patient treatment burden compared with first-generation agents.

Transforming Retinal Disease Care: Next-Generation Therapies for nAMD and DME to Reduce Burden and Optimize Outcomes

Michael A. Klufas, MD, discusses how second-generation retinal vascular agents like high-dose aflibercept 8 mg and faricimab show promising results for treating neovascular AMD and diabetic macular edema, with particular emphasis on extended treatment intervals up to 20 to 24 weeks and strategies for managing persistent exudation while maintaining vision.

Next-Generation Retinal Disease Treatments: Advancing Care in nAMD and DME 

Ferhina S. Ali, MD, MPH, discusses how emerging treatments and tailored management strategies can improve the care of patients with geographic atrophy in age-related macular degeneration, emphasizing the importance of patient education and individualized treatment plans.

Shaping the Future of Geographic Atrophy Management With Emerging Treatments

Murtaza Adam, MD, reviews the complement-based treatments for geographic atrophy (GA), discusses factors to consider before starting treatment, and shares insights from real-world cases in his practice to guide effective management strategies.

Spotlight on Geographic Atrophy: Promoting Early Detection and Treatment 

Dr. Carl D. Regillo, MD, FACS, FASRS provides a comprehensive overview of geographic atrophy, covering its diagnosis, current complement-based treatments, and insights from real-world cases in his practice to guide effective management strategies. 

Preserving Vision in Geographic Atrophy with Timely Diagnosis and Treatment

David Eichenbaum, MD, FASRS shares successful clinical experiences treating retinal diseases with second generation agents aflibercept 8 mg and faricimab, emphasizing improvements in visual acuity, anatomical features, and quality of life for patients.

Navigating Treatment Challenges in nAMD and DME

Dr David A. Eichenbaum shares treatment approaches and clinical advice for the management of AMD/DME.

David A. Eichenbaum, MD, FASRS, Management of AMD/DME

Dr Rishi Singh shares treatment approaches and clinical advice for the management of AMD/DME.

Rishi Singh, MD, Management of AMD/DME

Dr. Eduardo Uchiyama, shares treatment approaches and clinical advice for the management of uveitis.

Dr. Eduardo Uchiyama, MD Management of Uveitis

Thomas Albini, MD, shares treatment pearls and clinical insights regarding the management of uveitis.

Treatment Approaches for Uveitis